- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
PDL BioPharma Inc
+ Add to WatchlistPDLI:US
8.3700 USD 0.1600 1.95%As of 16:30:00 ET on 05/21/2013.
Snapshot for PDL BioPharma Inc (PDLI)
| Open: | 8.2400 | Day's Range: | 8.2200 - 8.3700 | Volume: | 1,941,739 |
|---|---|---|---|---|---|
| Previous Close: | 8.2100 | 52wk Range: | 6.1800 - 8.4300 | 1-Yr Rtn: | +41.86% |
Key Statistics for PDLI
| Current P/E Ratio (ttm) | 5.3929 |
|---|---|
| Estimated P/E(12/2013) | 5.0579 |
| Relative P/E vs. SPX | 0.3333 |
| Earnings Per Share (USD) (ttm) | 1.5400 |
| Est. EPS (USD) (12/2013) | 1.6420 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,162.67 |
| Shares Outstanding (M) | 140.00 |
| 30 Day Average Volume | 1,790,959 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 3.0065 |
| Dividend Indicated Gross Yield | 7.22% |
| Cash Dividend (USD) | 0.1500 |
| Last Dividend | 06/03/2013 |
| 5 Year Dividend Growth | -32.40% |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for PDLI
Company Profile & Key Executives for PDLI
PDL BioPharma Inc. discovers, develops, and markets therapies for serious or life-threatening illnesses, commercially focused on the acute care, hospital setting.
| John P McLaughlinPresident/CEO | Peter S GarciaVP/CFO/Acting Chief Acctg Ofcr |
| Christopher Lewis StoneVP/Secretary/General Counsel | Danny J Hart JrAsst Secy/Deputy Gen Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
PDLI News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page